Abstract
To demonstrate the economic impact of donepezil treatment for patients with mild to moderate Alzheimer’s disease (AD) in Japanese clinical settings, we conducted a cost-utility analysis using the Mark
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have